Fluorodeoxyuridine-mediated modulation of iododeoxyuridine incorporation and radiosensitization in human colon cancer cells in vitro and in vivo
- PMID: 1830239
Fluorodeoxyuridine-mediated modulation of iododeoxyuridine incorporation and radiosensitization in human colon cancer cells in vitro and in vivo
Abstract
A study was conducted to assess the potential of 5-fluoro-2'-deoxyuridine (FdUrd) to increase the incorporation and radiosensitizing properties of 5-iodo-2'-deoxyuridine (IdUrd) using HT29 human colon cancer cells both in vitro and in nude mice bearing these tumors as xenografts. The purpose of this study was to assess (a) whether FdUrd could increase IdUrd efficacy using clinically achievable concentrations of drugs; (b) the relationships among radiosensitization, DNA damage and repair, and analogue incorporation; and (c) whether FdUrd improved the selectivity of IdUrd incorporation into tumor cells compared to normal tissues. It was found that FdUrd, at clinically achievable concentrations (1-100 nM), significantly increased IdUrd incorporation under all conditions but particularly when the IdUrd concentration was less than or equal to 10 microM. FdUrd increased IdUrd-mediated radiosensitization in proportion to the increase in IdUrd incorporation. FdUrd potentiated the ability of IdUrd to increase radiation-induced DNA double-strand breaks and to slow their repair. When IdUrd alone (100 and 200 mg/kg/day) was infused into nude mice bearing tumors, the extent of thymidine replaced in the tumor was 1.6 +/- 0.4 (mean +/- SE) and 2.5 +/- 0.4%, respectively. The combination of FdUrd (0.1 mg/kg/day) and IdUrd (100 mg/kg/day) increased the incorporation in the tumor to 5.3 +/- 0.9% with less toxicity than resulted from the use of 200 mg/kg/day of IdUrd alone. These data show that FdUrd is an effective biomodulator, because, for the same extent of normal tissue incorporation, the combination of IdUrd and FdUrd produces significantly greater incorporation into the tumor compared to the use of IdUrd alone. Furthermore, they suggest that the regional application of FdUrd with IdUrd, either through the use of regional infusions or in combination with focused irradiation, could potentially improve the outcome of treatment of localized gastrointestinal cancer.
Similar articles
-
The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer.Cancer Res. 1992 Jul 1;52(13):3698-704. Cancer Res. 1992. PMID: 1617642
-
In vivo modulation of iododeoxyuridine metabolism and incorporation into cellular DNA by 5'-amino-5'-deoxythymidine in normal mouse tissues and two human colon cancer xenografts.Clin Cancer Res. 1996 Jun;2(6):981-9. Clin Cancer Res. 1996. PMID: 9816259
-
Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization.Cancer Res. 2003 Feb 15;63(4):838-46. Cancer Res. 2003. PMID: 12591735
-
Radiosensitization and cell kinetics: clinical implications for S-phase-specific radiosensitizers.Semin Oncol. 1992 Jun;19(3 Suppl 9):41-7. Semin Oncol. 1992. PMID: 1641656 Review.
-
Radiobiology and clinical application of halogenated pyrimidine radiosensitizers.Int J Radiat Biol. 1989 Nov;56(5):827-36. doi: 10.1080/09553008914552111. Int J Radiat Biol. 1989. PMID: 2573682 Review.
Cited by
-
Auger radiation targeted into DNA: a therapy perspective.Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1352-63. doi: 10.1007/s00259-006-0187-2. Epub 2006 Aug 8. Eur J Nucl Med Mol Imaging. 2006. PMID: 16896663 Review.
-
Short fluorodeoxyuridine exposure of different human glioblastoma lines induces high-level accumulation of S-phase cells that avidly incorporate 125I-iododeoxyuridine.Eur J Nucl Med Mol Imaging. 2006 May;33(5):613-20. doi: 10.1007/s00259-005-0009-y. Epub 2006 Feb 1. Eur J Nucl Med Mol Imaging. 2006. PMID: 16450135